The Sanofi vaccines division Sanofi Pasteur has launched Japanese encephalitis (JE) vaccine, IMOJEV, in Australia.
Australian Health Authorities approved the live-attenuated JE vaccine for people aged 12 months and older, based on data from clinical studies demonstrating the safety and efficacy of IMOJEV.
Single dose vaccine is approved for adults while a dose for primary immunization besides booster doses is recommended for children.
Austin Hospital travel medicine head Joseph Torresi said, "IMOJEV has shown to provide seroprotection to over 90% adults just 2 weeks after vaccination with one dose which provides strong motive to be vaccinated before traveling."
IMOJEV demonstrated a significant immunogenicity profile with the ability to produce a protective immune response with single dose in studies conducted across US, Australia, Thailand, and the Philippines.
Sanofi Pasteur Australia general manager Russell Jacobson said IMOJEV vaccine provides protection against Japanese encephalitis in single dose.
"IMOJEV makes scheduling a trip in the Asia Pacific region, or other endemic areas, more convenient for business travellers, tourists and the military alike," Jacobson added.
